{
    "id": 3962,
    "name": "thyroid gland follicular carcinoma",
    "source": "DOID",
    "definition": "A differentiated thyroid gland carcinoma that has_material_basis_in follicular cells. [url:http\\://en.wikipedia.org/wiki/Follicular_thyroid_cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3962",
    "evidence": [
        {
            "id": 8215,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an follicular thyroid cancer cell line harboring PTEN R130* and loss of one PTEN allele (PMID: 21289267).",
            "molecularProfile": {
                "id": 4166,
                "profileName": "PTEN R130*"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6573,
                    "pubMedId": 21289267,
                    "title": "The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21289267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9834,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited tumor growth, decreased tumor cell proliferation, and decreased MYC expression in a mouse model of follicular thryroid carcinoma harboring KRAS G12D and THRB P447fs*16 (PMID: 27440272).",
            "molecularProfile": {
                "id": 27134,
                "profileName": "KRAS G12D THRB P447fs"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7659,
                    "pubMedId": 27440272,
                    "title": "Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18768,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18770,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18772,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18786,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18788,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18789,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01723202",
            "title": "Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02145143",
            "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02152995",
            "title": "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02211222",
            "title": "An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer",
            "phase": "Phase I",
            "recruitment": "Approved for marketing",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02393690",
            "title": "Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02456701",
            "title": "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02702388",
            "title": "Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02973997",
            "title": "Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03215095",
            "title": "RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03914300",
            "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2068,
                    "therapyName": "Cabozantinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04321954",
            "title": "Lenvatinib in Locally Advanced Invasive Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        }
    ]
}